CEND-1

DRUG4 trials

Sponsors

Lisata Therapeutics, Inc., Qilu Pharmaceutical Co., Ltd., Anup Kasi

Conditions

Colon CancerDigestive CancerPancreas CancerPancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

CompletedNCT03517176

Lisata Therapeutics, Inc.Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2018-07-31End: 2020-06-19Updated: 2024-08-28

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

CompletedNCT05052567

Qilu Pharmaceutical Co., Ltd.Pancreatic Cancer

Start: 2021-10-21End: 2024-06-29Updated: 2024-09-04

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

Active, not recruitingNCT05121038

Anup KasiColon Cancer, Digestive Cancer, Pancreas Cancer

Start: 2021-10-20End: 2026-09-30Target: 50Updated: 2024-12-17

Phase 2

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

RecruitingNCT06261359

Qilu Pharmaceutical Co., Ltd.Pancreatic Ductal Adenocarcinoma (PDAC)

Start: 2024-03-19End: 2026-10-31Target: 120Updated: 2024-09-04

Related Papers

Abstract A070: CENDIFOX: Phase I/II Trial of CEND-1 (LSTA1, certepetide) with Neoadjuvant mFOLFIRINOX in Resectable and Borderline Resectable PDAC

Cancer Research2025-09-28

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2023-06-012 citations

Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study.

2022-07-0653 citations

Phase Ib/IIa trial of CEND‐1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX).

Journal of Clinical Oncology2022-06-016 citations